Medical Psilocybin (magic mushrooms) used by Charles Grob In Psychiatry - Good Idea?

  • Thread starter Thread starter aspergers@40
  • Start date Start date
  • Tags Tags
    Idea
AI Thread Summary
The discussion centers on the potential of psychedelic substances, particularly psilocybin and MDMA, as therapeutic tools in psychotherapy. Dr. Charles Grob's research is highlighted, noting its success in treating various mental health issues, although concerns about the regulatory status of these substances as Schedule I drugs are raised. The conversation touches on the challenges of proving efficacy through double-blind studies, especially given the complexities of administering hallucinogens versus placebos. The placebo effect and patient engagement are discussed as significant factors in therapeutic outcomes. There is a recognition of the untapped potential of psychedelics like MDMA and ketamine in treating conditions such as depression, despite fears of abuse and adverse effects. The dialogue suggests a growing interest in exploring these substances for their therapeutic benefits, especially for conditions like Asperger's syndrome, while acknowledging the need for careful study designs and regulatory considerations.
aspergers@40
Messages
61
Reaction score
0
I was intrigued when I read about this and the many success stories that he's had with his patients. Is this a valuable yet underused medical treatment in your opinion? Dr. Charles Grob - Psychedelic Researcher
 

Attachments

  • CharlieGrob.jpg
    CharlieGrob.jpg
    12.1 KB · Views: 432
Biology news on Phys.org
The only use for magic shrooms that I know of, offlabel, is for cluster headaches
 
Not in the US. It is a scheduled I substance which means it has no redeeming medical value whatsoever.

Numerous psychotherapists and researchers have enjoyed considerable success with unapproved methods. And really I should not imply that such success is limited to issues of the mind. Does laying on of hands help, twirling psychic energy, acupuncture, homeopathy, and a very long list?

I don't want to seem pedantic here; we are all familiar with the placebo effect. We are also aware of the biases which insinuate themselves into any therapist/patient relationship. Besides the placebo effect, the therapist (hopefully) believes in the therapy offered and is more likely than not to see a favorable influence. Patient, so encouraged, believes to be better, and you get this nice positive feedback summoning the patient towards improvement. The other effect you will see is the people pleasing effect--some patients are either naturally people pleaers, or become like a pet student who want to be the a+ student become so engaged with apparent improvement, they actually do...via a placebo like effect or for lack of a better term, fake it til you make it--the increased engagement with life and activity revive the pleasure pathways, and the brain bbenefits from the stimulation.

I am aware of Grob's work while I believe it was conducted in a scrupulous and most conscientious fashion, still wonder to what extent these warning I mentioned might apply. Forgive a bad pun, but the acid test of any intervention is a double blinded study where neither the observer or the subject knows what's up. They do this with any psychoactive drug before it gets to market.

With antidepressants like Prozac the separation is not that great. Placebo response is about 30%, active drug maybe 50%.

So getting back to your question--how do you administer a hallucinogen vs a placebo?

I don't discount this research whatsoever. It is just a sticky wicket to prove efficacy and with a fear of such modalities dating back to "reefer madness", you have a tough sale to get permission to do so. Things have loosened up a bit since Reagan but still a tough road to hoe. There are a couple of exceptions I can look up if interested.

Maybe the one iilegal drug with the most untapped potential for psychotherapy is something like Ecstasy. This was widely used in the bay area and other sites in the late 70' and early 80's. Therapists were reporting astonishing results with very difficult to treat patients in individual and marital counseling.

So that's the state of things--potentially promising therapies are outlawed for fear of abuse potential and adverse side effects, and in many cases, no way of assessing theirr itherapeutic impact without the non-doubleblind situation issues requiring very good study designs.

Liability issues are rampant, professional credibility will be forsaken in most quarters, why bother?? Personally, I feel the greatest potential loss is with ketamine. It has been shown to bring about VERY rapid resolution of depression yet, it can be abused, is lethal in overdose... Much like any garden variety pain reliever. ?? I doubt any opiate could pass current FDA standards if discovered yesterday.
 
Thanks for the input, much appreciated. I read about it in Discover Magazine of the Brain, and the report seemed quite favourable, with six new studies involving MDMA, acid etc. I find marijuana as a good passifier of my asperger's anxiety. Like you say, it's a question of delicate balance. I would be a willing guinea-pig for the psilocybin incidentally. Any relief from particularly acute symptoms shouldn't be denied from patients imo.
 
I'll have to find the issue. I would be particularly interested to see whether MDMA has been in tried with connection of Aspergers patients. MDMA and simuilar compounds are as far as I know the only known chemical empathogens, and may be of great value in developing these capacities. Come to think of it, I know a few CEO's, aka sociopaths, who might benefit from such.
 
denverdoc said:
I'll have to find the issue. I would be particularly interested to see whether MDMA has been in tried with connection of Aspergers patients. MDMA and simuilar compounds are as far as I know the only known chemical empathogens, and may be of great value in developing these capacities. Come to think of it, I know a few CEO's, aka sociopaths, who might benefit from such.
lol.
 
https://www.discovermagazine.com/the-deadliest-spider-in-the-world-ends-lives-in-hours-but-its-venom-may-inspire-medical-miracles-48107 https://en.wikipedia.org/wiki/Versutoxin#Mechanism_behind_Neurotoxic_Properties https://www.sciencedirect.com/science/article/abs/pii/S0028390817301557 (subscription or purchase requred) he structure of versutoxin (δ-atracotoxin-Hv1) provides insights into the binding of site 3 neurotoxins to the voltage-gated sodium channel...
Popular article referring to the BA.2 variant: Popular article: (many words, little data) https://www.cnn.com/2022/02/17/health/ba-2-covid-severity/index.html Preprint article referring to the BA.2 variant: Preprint article: (At 52 pages, too many words!) https://www.biorxiv.org/content/10.1101/2022.02.14.480335v1.full.pdf [edited 1hr. after posting: Added preprint Abstract] Cheers, Tom
Back
Top